British scientists have unraveled how a non-intoxicating component of cannabis acts in key brain areas to reduce abnormal activity in patients at risk of psychosis, suggesting the ingredient could become a novel anti-psychotic medicine.

While regular use of potent forms cannabis can increase the chances of developing psychosis, the chemical cannabidiol or CBD appears to have the opposite effect.

CBD is the same cannabis compound that has also shown benefits in epilepsy, leading in June to the first U.S. approval of a cannabis-based drug, a purified form of CBD from GW Pharmaceuticals.

Previous research at King’s College London had shown that CBD seemed to counter the effects of tetrahydrocannabinol or THC, the substance in cannabis that makes people high. But how this happened was a mystery.

Now, by scanning the brains of 33 young people who were experiencing distressing psychotic symptoms but had not been diagnosed with full-blown psychosis, Sagnik Bhattacharyya and colleagues showed that giving CBD capsules reduced abnormal activity in the striatum, medial temporal cortex and midbrain.

Abnormalities in all three of these brain regions have been linked to the onset of psychotic disorders such as schizophrenia.

Most current anti-psychotic drugs target the dopamine chemical signaling system in the brain, while CBD works in a different way.

Your opinion is valuable. Take this quick survey to help us improve the website and content

Significantly, the compound is very well tolerated, avoiding the adverse side effects such as weight gain and other metabolic problems associated with existing medicines.